Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS [Phase 3]
A Phase IIIb multicenter international trial evaluating EK-12 for Relapsing-Remitting Multiple Sclerosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
A completed study evaluating changes in immunoglobulin levels in patients with relapsing multiple sclerosis treated with anti-CD20 therapies…
-
CLINICAL_TRIALS research · 2024-07-24Clinical Trial Update: Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
This trial update describes the development of a camera-based gait quality measure for people with multiple sclerosis and notes that recruit…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 4]
The Phase 4 trial evaluating the radiological onset of action after starting subcutaneous natalizumab in relapsing-remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration [Phase 3]
Phase 3 trial evaluating extended-interval dosing of natalizumab in relapsing-remitting multiple sclerosis patients switching from standard …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-06-04Clinical Trial Update: Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
This clinical trial update evaluates whether sonographic measurement of the optic nerve is a productive diagnostic approach in Relapsing-Rem…
-
CLINICAL_TRIALS research · 2024-06-03Clinical Trial Update: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
Biogen's Canadian multicenter observational study of natalizumab (Tysabri) in patients with early Relapsing-Remitting Multiple Sclerosis has…
-
CLINICAL_TRIALS withdrawal · 2024-06-03Clinical Trial Update: A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a [Phase 4]
A Phase 4 proof-of-concept study evaluating retinal nerve fiber layer changes in relapsing-remitting multiple sclerosis patients treated wit…
-
CLINICAL_TRIALS research · 2024-05-22Clinical Trial Update: A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy, pharmacokinetics, pharmacodynamics, and safety of CT-P53 versus Ocrevus in relapsing-re…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: A Study for Tysabri Participant Preference
This clinical trial update covers a study evaluating participant preferences for Tysabri (natalizumab) in Relapsing-Remitting Multiple Scler…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis [NA]
A clinical trial is evaluating whether adding conjugated linoleic acid and the probiotic Vivomixx to first-line immunotherapy improves outco…
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This clinical trial update reports the completion of a study evaluating the effectiveness and safety of Mayzent (fingolimod) in Chinese pati…
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients [Phase 4]
Phase 4 trial investigating effects of oral cladribine on remyelination and inflammation in relapsing-remitting multiple sclerosis.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Accord (dimethyl fumarate) — Accord Healthcare S.L.U.
EMA revoked the marketing authorization for Dimethyl fumarate Accord for multiple sclerosis indications.
-
CLINICAL_TRIALS trial_result · 2023-12-01Clinical Trial Update: A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS [Phase 3]
Phase 3 trial assessing efficacy, safety, and tolerability of monthly long-acting GA Depot IM injection in relapsing-remitting multiple scle…
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Phase II Clinical Trial of OCH-NCNP1 [Phase 2]
Phase II clinical trial update for OCH-NCNP1 completed; study conditions include relapsing-remitting and secondary progressive multiple scle…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® [Phase 3]
Phase 3 trial evaluating the efficacy and safety of the biosimilar PB006 versus Tysabri in relapsing-remitting multiple sclerosis has comple…
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS [Phase 3]
Non-inferiority Phase 3 trial comparing rituximab to ocrelizumab in relapsing multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2023-04-27Clinical Trial Update: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 trial update on personalized extended interval dosing of natalizumab for relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2023-04-21Clinical Trial Update: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 2]
Phase 2 study update for orelabrutinib in relapsing-remitting multiple sclerosis is reported as ongoing with no published results yet.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update for intranasal insulin in multiple sclerosis across Phase 1 and Phase 2 has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: An Extension of the TG1101-RMS201 Trial [Phase 2]
An extension study of TG1101-RMS201 in relapsing-remitting multiple sclerosis has completed Phase 2.
-
FDA approval · 2022-11-16FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approved Biogen's supplemental application for VUMERITY (diroximel fumarate).
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial update on efficacy and safety of peginterferon beta-1a (CinnaGen) in relapsing remitting multiple sclerosis showed results aft…
-
CLINICAL_TRIALS trial_result · 2022-10-18Clinical Trial Update: Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]
Phase 3 trial update for Xacrel (Ocrelizumab) in relapsing-remitting multiple sclerosis reports efficacy and safety data.